9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Mesothelioma

Estimated Enrollment: 33

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: Objective tumor response rate (complete response or partial response) as assessed by modified RECIST criteria,  Time to disease progression,  Overall survival, Safety

Interventions: bortezomib, quality-of-life assessment

Phase:

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: None (Open Label),Primary Purpose: Treatment

Primary Completion Date: December 2009

Completion Date:

Last  Posted Date: December 31, 2014

Location: Universitair Ziekenhuis Gent, Ghent, Belgium

Website Link: https://ClinicalTrials.gov/show/NCT00513877

Was this article helpful?
Dislike 0